Vps34 (the human class III phosphoinositide 3-kinase) is a lipid kinase involved in vesicle trafficking and autophagy and therefore constitutes an interesting target for cancer treatment. Because of the lack of specific Vps34 kinase inhibitors, we aimed to identify such compounds to further validate the role of this lipid kinase in cancer maintenance and progression. Herein, we report the discovery of a series of tetrahydropyrimidopyrimidinone derivatives. Starting with hit compound 1a, medicinal chemistry optimization led to compound 31. This molecule displays potent activity, an exquisite selectivity for Vps34 with excellent properties. The X-ray crystal structure of compound 31 in human Vps34 illustrates how the unique molecular features of the morpholine synthon bestows selectivity against class I PI3Ks. This molecule exhibits suitable in vivo mouse PK parameters and induces a sustained inhibition of Vps34 upon acute administration. Compound 31 constitutes an optimized Vps34 inhibitor that could be used to investigate human cancer biology.
Most of the phosphoinositide-3 kinase (PI3K) kinase inhibitors currently in clinical trials for cancer treatment exhibit pan PI3K isoform profiles. Single PI3K isoforms differentially control tumorigenesis, and PI3Kβ has emerged as the isoform involved in the tumorigenicity of PTEN-deficient tumors. Herein we describe the discovery and optimization of a new series of benzimidazole- and benzoxazole-pyrimidones as small molecular mass PI3Kβ-selective inhibitors. Starting with compound 5 obtained from a one-pot reaction via a novel intermediate 1, medicinal chemistry optimization led to the discovery of compound 8, which showed a significant activity and selectivity for PI3Kβ and adequate in vitro pharmacokinetic properties. The X-ray costructure of compound 8 in PI3Kδ showed key interactions and structural features supporting the observed PI3Kβ isoform selectivity. Compound 8 achieved sustained target modulation and tumor growth delay at well tolerated doses when administered orally to SCID mice implanted with PTEN-deficient human tumor xenografts.
A novel class of heat shock protein 90 (Hsp90) inhibitors was developed after a low throughput screen (LTS) of a focused library containing approximately 21K compounds selected by virtual screening. The initial [1-{3-H-imidazo[4-5-c]pyridin-2-yl}-3,4-dihydro-2H-pyrido[2,1-a]isoindole-6-one] (1) compound showed moderate activity (IC(50) = 7.6 μM on Hsp82, the yeast homologue of Hsp90). A high-resolution X-ray structure shows that compound 1 binds into an "induced" hydrophobic pocket, 10-15 Å away from the ATP/resorcinol binding site. Iterative cycles of structure-based drug design (SBDD) and chemical synthesis led to the design and preparation of analogues with improved affinity. These optimized molecules make productive interactions within the ATP binding site as reported by other Hsp90 inhibitors. This resulted in compound 8, which is a highly potent inhibitor in biochemical and cellular assays (K(d) = 0.35 nM on Hsp90; IC(50) = 30 nM on SKBr3 mammary carcinoma cells) and in an in vivo leukemia model.
More than 75% of breast cancers are estrogen receptor
alpha (ERα)
positive (ER+), and resistance to current hormone therapies occurs
in one-third of ER+ patients. Tumor resistance is still ERα-dependent,
but mutations usually confer constitutive activation to the hormone
receptor, rendering ERα modulator drugs such as tamoxifen and
aromatase inhibitors ineffective. Fulvestrant is a potent selective
estrogen receptor degrader (SERD), which degrades the ERα receptor
in drug-resistant tumors and has been approved for the treatment of
hormone-receptor-positive metastatic breast cancer following antiestrogen
therapy. However, fulvestrant shows poor pharmacokinetic properties
in human, low solubility, weak permeation, and high metabolism, limiting
its administration to inconvenient intramuscular injections. This
Drug Annotation describes the identification and optimization of a
new series of potent orally available SERDs, which led to the discovery
of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (43d),
showing promising antitumor activity in breast cancer mice xenograft
models and whose properties warranted clinical evaluation.
From Difluorocyclopropene to Difluorocyclopropylidene.-Difluorocyclopropenes of type (III), easily obtained from the addition reaction of the corresponding acetylenes (I) and difluorocarbene, undergo a stereoselective reduction transposition in the presence of K-Selectride to form the substituted difluorocyclopropylidene compounds ( IV) and (V), which are potential building blocks for the synthesis of new pyrethroid insecticides.-(BABIN, D.; PILORGE, F.; DELBARRE, L. M.; DEMOUTE, J. P.; Tetrahedron 51 (1995) 35, 9603-9610; Agrochem. Res. Dep., Roussel Uclaf, F-93230 Romainville, Fr.; EN)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.